Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Unicycive Therapeutics, Inc. (UNCY)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
0.5277+0.0177 (+3.47%)
At close: 04:00PM EST
0.5200 -0.01 (-1.46%)
After hours: 06:53PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Slow Stochastic

Slow Stochastic

Performance Outlook
Previous Close0.5100
Open0.5145
Bid0.5000 x 800
Ask0.5450 x 1400
Day's Range0.4500 - 0.5590
52 Week Range0.4000 - 1.6400
Volume627,378
Avg. Volume321,021
Market Cap7.962M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.9480
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.38
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for UNCY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Unicycive Therapeutics, Inc.
    Daily – Vickers Top Insider Picks for 11/30/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • GlobeNewswire

    Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea

    Develops Renazorb opportunity in new market for patients with hyperphosphatemia Agreement includes upfront payment, royalties, and milestone payments LOS ALTOS, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that it has entered into an exclusive license agreement with Lotus Pharmaceutical (“Lotus”, Taiwan TWSE ticker: 1795) , a leading global pharm

  • GlobeNewswire

    Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation’s Spring Clinical Meetings

    Data support UNI-494’s potential to treat acute kidney disease and underscore the phosphate binding benefits of Renazorb as a potential treatment for hyperphosphatemiaLOS ALTOS, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that three abstracts have been accepted for presentation at the National Kidney Foundation’s (NFK) upcoming Spring Clinical M

  • GlobeNewswire

    Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023

    Growing body of clinical evidence support the potential of Renazorb and UNI-494 to effectively treat hyperphosphatemia and acute kidney disease, respectivelyLOS ALTOS, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that four abstracts have been accepted for presentation at the upcoming International Society of Nephrology’s World Congress of Nephrol

Advertisement
Advertisement